argenx drops after trial futility prompts investigation notice
argenx shares fell after the company said an independent committee found its Phase 3 UNITY study in Sjögren's disease was unlikely to meet its primary endpoint and would be discontinued. The notice says investors may submit loss details for a pending investigation.